Recipharm offers manufacturing support to vaccine trial from ImmBIO and iiCON
Charlie Blackie-Kelly | October 21, 2025 | News story | Manufacturing and Production | ImmunBiology, Infection Innovation Consortium, Recipharm, Vaccine, pneumococcal disease
Recipharm, a contract development and manufacturing organisation (CDMO), has successfully manufactured PnuBioVax, a new protein-based vaccine against pneumococcal disease, developed by ImmunoBiology (ImmBIO) and the Infection Innovation Consortium (iiCON) for a phase 2a clinical trial.
PnuBioVax is designed to target proteins common across pneumococcal strains, which cause pneumococcal disease – a leading preventable cause of death in children worldwide, particularly in low- and middle-income countries.
ImmBIO developed the vaccine and completed phase 1 safety and immunogenicity studies, with iiCON joining the programme to lead the next stage of development. The vaccine’s advancement is supported by a £3.2m Medical Research Council (MRC)-funded trial delivered by iiCON.
Recipharm led the current Good Manufacturing Practice (cGMP) production of PnuBioVax, scaling up output from the phase 1 run and implementing enhanced compliance and quality checks.
This manufacturing run will support a phase 2a trial in Malawi, investigating the vaccine’s efficacy against multiple pneumococcal strains and informing future large-scale trials and commercialisation strategies.
Charlie Blacke-Kelly
Related Content
BioNet receives positive EMA opinion on new pertussis vaccine
BioNet has received a positive opinion from the Committee for Medicinal Products for Human Use …
Recipharm designates Germany site as Centre of Excellence
The multi-product facility recently underwent significant renovations
EMA lifts temporary ban on chikungunya vaccine Ixchiq following safety review
After completing a safety review of Ixchiq – a vaccine for chikungunya – the European …
